**Name of Journal:** *World Journal of Stem Cells*

**Manuscript NO:** 75984

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Sinomenine promotes differentiation of induced pluripotent stem cells into immature dendritic cells with high induction of immune tolerance**

Huang XY *et al*. SN promotes iPSCs differentiate to imDC

Xiao-Yan Huang, Zhan-Kui Jin, Meng Dou, Bing-Xuan Zheng, Xiang-Rong Zhao, Qing Feng, Yang-Meng Feng, Xiang-Long Duan, Pu-Xun Tian, Cui-Xiang Xu

**Xiao-Yan Huang, Xiang-Rong Zhao, Qing Feng, Yang-Meng Feng, Cui-Xiang Xu,** Shaanxi Provincial Key Laboratory of Infection and Immune Diseases, Shaanxi Provincial People’s Hospital, Xi'an 710068, Shaanxi Province, China

**Zhan-Kui Jin,** Department of Orthopedics, Shaanxi Provincial People’s Hospital, Xi'an 710068, Shaanxi Province, China

**Meng Dou, Bing-Xuan Zheng, Pu-Xun Tian,** Department of Kidney Transplantation, The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an 710061, Shaanxi Province, China

**Xiang-Long Duan,** Second Department of General Surgery, Shaanxi Provincial People's Hospital, Xi'an 710068, Shaanxi Province, China

**Author contributions:** Huang XY, Jin ZK, Tian PX and Xu CX conceived and designed the study, and drafted the article; Dou M, Zhao XR, Feng Q, Feng YM and Duan XL performed the experiments; Huang XY and Xu CX analyzed the data; Huang XY, Jin ZK, Dou M and Xu CX performed data analysis; all authors contributed to the collection of literature data, reviewed the manuscript, and approved the version to be published.

**Supported by** National Natural Science Foundation of China, No. 81900686; Science and Technology Incubation Fund Project of Shaanxi Provincial People’s Hospital, No. 2020YXM-08; Technology Talent Support Program of Shaanxi Provincial People’s Hospital, No. 2021BJ-07; Key Projects of Shaanxi Provincial Department of Education, No. 21JS038; and Medical Research Development Fund of Beijing Kangmeng Charity Foundation, No. 7B202010.

**Corresponding author: Cui-Xiang Xu, PhD, Chief Doctor, Doctor, Senior Researcher,** Shaanxi Provincial Key Laboratory of Infection and Immune Diseases, Shaanxi Provincial People’s Hospital, No. 256 West Road, Beilin District, Xi'an 710068, Shaanxi Province, China. xucuixiang1129@163.com

**Received:** February 25, 2022

**Revised:** May 16, 2022

**Accepted:** July 11, 2022

**Published online:** August 26, 2022

**Abstract**

BACKGROUND

Immature dendritic cells (imDCs) play an important role in the induction of donor-specific transplant immunotolerance. However, these cells have limitations, such as rapid maturation and a short lifespan *in vivo*. In previous studies, induced pluripotent stem cells (iPSCs) differentiated into imDCs, and sinomenine (SN) was used to inhibit the maturation of imDCs.

AIM

To study the capacity of SN to maintain iPSC-derived imDCs (SN-iPSCs-imDCs) in an immature state and the mechanism by which SN-iPSCs-imDCs induce immunotolerance.

METHODS

In this study, mouse iPSCs were induced to differentiate into imDCs in culture medium with or without SN (iPSCs-imDCs and SN-iPSCs-imDCs). The imDC-related surface markers, endocytotic capacity of fluorescein isothiocyanate-Dextran and apoptosis were analyzed by flow cytometry. The effects of iPSCs-imDCs and SN-iPSCs-imDCs on T-cell stimulatory function, and regulatory T (Treg) cell proliferative function *in* *vitro* were analyzed by mixed lymphocyte reaction. Cytokine expression was detected by ELISA. The apoptosis-related proteins of iPSCs-DCs and SN-iPSCs-DCs were analyzed by western blotting. The induced immunotolerance of SN-iPSCs-DCs was evaluated by treating recipient Balb/c skin graft mice. Statistical evaluation of graft survival was performed using Kaplan–Meier curves.

RESULTS

Both iPSCs-imDCs and SN-iPSCs-imDCs were successfully obtained, and their biological characteristics and ability to induce immunotolerance were compared. SN-iPSCs-imDCs exhibited higher CD11c levels and lower CD80 and CD86 levels compared with iPSCs-imDCs. Reduced major histocompatibility complex II expression, worse T-cell stimulatory function, higher Treg cell proliferative function and stronger endocytotic capacity were observed with SN-iPSCs-imDCs (*P* < 0.05). The levels of interleukin (IL)-2, IL-12, interferon-γ in SN-iPSCs-imDCs were lower than those in iPSCs-imDCs, whereas IL-10 and transforming growth factor-β levels were higher (*P* < 0.05). The apoptosis rate of these cells was significantly higher (*P* < 0.05), and the expression levels of cleaved caspase3, Bax and cleaved poly(ADP-ribose) polymerase were higher after treatment with lipopolysaccharides, but Bcl-2 was reduced. In Balb/c mice recipients immunized with iPSCs-imDCs or SN-iPSCs-imDCs 7 d before skin grafting, the SN-iPSCs-imDCs group showed lower ability to inhibit donor-specific CD4+ T-cell proliferation (*P* < 0.05) and a higher capacity to induce CD4+CD25+FoxP3+ Treg cell proliferation in the spleen (*P* < 0.05). The survival span of C57bl/6 skin grafts was significantly prolonged in immunized Balb/c recipients with a donor-specific pattern.

CONCLUSION

This study demonstrated that SN-iPSCs-imDCs have potential applications *in vitro* and *in vivo* for induction of immunotolerance following organ transplantation.

**Key Words:** Immature dendritic cells; Induced pluripotent stem cells; Sinomenine; Immune tolerance; Organ transplantation

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Huang XY, Jin ZK, Dou M, Zheng BX, Zhao XR, Feng Q, Feng YM, Duan XL, Tian PX, Xu CX. Sinomenine promotes differentiation of induced pluripotent stem cells into immature dendritic cells with high induction of immune tolerance. *World J Stem Cells* 2022; 14(8): 599-615

**URL**: https://www.wjgnet.com/1948-0210/full/v14/i8/599.htm

**DOI**: https://dx.doi.org/10.4252/wjsc.v14.i8.599

**Core Tip:** Immature dendritic cells (imDCs) play an important role in the induction of donor-specific transplant immune tolerance. However, these cells have limitations, such as rapid maturation and a short lifespan. This study focused on exploring sinomenine (SN) to promote differentiation of induced pluripotent stem cells (iPSCs) into imDCs (SN-iPSCs-imDCs), and found SN-iPSCs-imDCs with worse donor-specific T-cell stimulatory function, and higher regulatory T-cell proliferative function *in vitro* and *in vivo* to induce high immune tolerance. It provided a new idea for the application of the combination of traditional Chinese medicine and modern new technologies in transplantation immunity.

**INTRODUCTION**

Although solid organ transplantation has become the most effective and promising treatment option for end-stage organ failure, it is limited by immune rejection. The advancement of medical technology and development of new immunosuppressive regimens have lowered the rates of acute rejection but appear to have had little impact on the incidence of chronic rejection; the principal cause of late graft loss[1,2]. Therefore, it is necessary to seek a therapeutic approach with minimal side effects and high safety and effectiveness to inhibit chronic rejection, ultimately inducing a state of donor-specific tolerance.

Dendritic cells (DCs) are the most potent antigen-presenting cells and play a dual role in the immune response. Mature DCs participate in the priming of naïve T cells to initiate an immune response, while immature DCs (imDCs) induce immune hyporesponsiveness or tolerance[3]. Cumulative evidence has demonstrated that imDCs induce immunotolerance and immune hyporesponsiveness because they do not induce expression of costimulatory molecules or promote the proliferation of CD4+CD25+ regulatory T (Treg) cells[4-6]. However, DCs constitute only 1% of human peripheral blood[7], and can be obtained from a limited number of sources. Additionally, DCs from external sources are prone to maturation after infusion *in vivo*.

Induced pluripotent stem cells (iPSCs) display the classic features of embryonic stem cells such as differentiation capacity and immunomodulation. Importantly, they have the main advantages of convenient acquisition, broad applicability, noninvasiveness, and lack of immunorejection and ethical issues[8]. They can also be induced into DCs *in vitro*[9], which solves the problem of limited sources for DCs. However, maintaining an immature state for DCs over a long period is another critical challenge to be addressed.

Sinomenine (SN), a Chinese medicinal product, is reported to be a potential therapeutic tool for inducing immunotolerance[10,11]. Some studies have confirmed that donor-derived DCs infused before transplantation were maintained in the immature stage by SN, which increased splenic FoxP3+ Treg cells in recipient rats after renal allotransplantation[12] and prolonged the survival time of allografts[13]. In addition, SN reduced the expression of costimulatory molecules on DCs, such as CD86 and CD40[14], and enhanced the function of CD4+CD25+ Treg cells[15]. However, whether SN can maintain the immature stage of iPSC-derived DCs to induce immune toleranceremains to be investigated.

We aimed to study the capacity of SN to maintain iPSC-imDCs (SN-iPSCs-imDCs) in an immature state as well as the mechanism by which SN-iPSCs-imDCs induce immunotolerance *in vitro*. Our findings should provide a theoretical and experimental basis for the application of SN-iPSCs-imDCs for the induction of immunotolerance following organ transplantation.

**MATERIALS AND METHODS**

***Cell lines and reagents***

iPSCs lines MiPS.5 were purchased from Shanghai Sisansai Biological Technology Co Ltd (Catalogue No. 0225-100) and maintained in serum-free and feeder-free medium (DMEM/F12, Neurobasal medium, 0.5% N2, 1% B27, 0.1% 2-mercaptoethanol (ME), 1% Penicillin-Streptomycin, 0.1‰ StemoleculeTM PD0325901, 0.32‰ StemoleculeTM CHIR99021, 0.1‰ LIF). Mouse bone marrow stromal cells, OP9, were maintained in DMEM supplemented with 10% fetal calf serum (FCS) and seeded onto gelatin-coated dishes before use as feeder cells. Recombinant mouse interleukin (IL)-4 and granulocyte macrophage colony-stimulating factor (GM-CSF) were obtained from Perprotech (London, United Kingdom). Lipopolysaccharide (LPS) was purchased from Sigma Chemical (St. Louis, MO). Monoclonal antibodies of rabbit anti-mouse fluorescein isothiocyanate (FITC)-CD45, FITC-CD11b, FITC-CD80, FITC-CD86, FITC-MHC-II, FITC-CD11c, CD4, CD25, FoxP3, Bcl-2, Bax, Caspase3, and poly(ADP-ribose) polymerase (PARP) were obtained from Biolegend (California, United States). SN was obtained from Xidiai Chemical Industrial Development Co Ltd (Shanghai, China).

***SN optimal concentration screening assay***

iPSCs were treated with different concentrations of SN (0, 50, 100 or 200 μM). The optimal concentration of SN was determined with the Cell Counting Kit-8 (CCK-8) assay. The optimal concentration of the drug was defined as the maximum administered concentration at which cell viability was > 95%.

***iPSC identification***

Polymerase chain reaction (PCR) Total RNA was extracted from resuscitated iPSCs, and reverse transcription was performed on ice to obtain cDNA. Afterward, quantitative PCR (qPCR) was performed using the Green PCR Master Mix System (Thermo Fisher Scientific). β-actin expression was used to normalize all the data. The primer sequences used are listed in Table 1.

***Alkaline phosphatase staining***

Resuscitated iPSCs were cultured on sterile glass slides for 24 h, fixed, washed, and stained in a freshly prepared alkaline-dye mixture. The cells were exposed to the dark at 18-26 °C for 15 min, then observed under a microscope and photographed for analysis.

***Karyotype analysis***

iPSCs were collected and treated with 2% colchicine for 2 h, then treated with 0.075 M KCL in 37 °C for 30 min, and pre-fixed with a newly prepared fixative (methanol: Glacial acetic acid = 3:1). The supernatant was discarded, the cells were fixed again for 30 min, dropped onto slides, and treated with 0.125% trypsin solution for 2 s. After staining with Giemsa stain for 10 min, karyotype analysis was performed using chromosome karyotype analysis software (BEION V4.20 -C).

***Teratoma formation***

iPSCs (5 × 106) were injected subcutaneously into the right flank of Balb/c nude mice. The mice were observed to determine the time of teratoma formation and differentiation into ectoderm, mesoderm, and endoderm tissue.

***Differentiation culture***

The procedure for inducing differentiation of iPSCs into DCs comprised three stages[9]. Stage 1: In the presence or absence of 100 μM SN, iPSCs were suspended in α-minimal essential medium (MEM) supplemented with 20% FCS and seeded (105 cells *per* dish) onto OP9 cell layers. On day 7, the cells were collected for stage 2. Stage 2: In the presence or absence of 100 μM SN, cells harvested from the stage 1 culture were resuspended in α-MEM supplemented with 20% FCS, GM-CSF (10 ng/mL), and 2-ME (50 mmol/L) for 6 d. Stage 3: In the presence or absence of 100 μM SN, the cells were cultured in RPMI-1640 medium supplemented with 10% FCS, 100 μM SN, GM-CSF, and 2-ME without feeder cells. On day 5 or 6 after initiation of stage 3, the cells were stimulated with LPS (5 mg/mL) for 48 h then collected for subsequent analysis.

***Mixed lymphocyte reaction***

CD4+ T cells from Balb/c mouse spleen were isolated with MACS immunomagnetic beads. The iPSCs-DCs and SN-iPSCs-DCs groups were treated with 25 μg/mL mitomycin. The control consisted of RPMI-1640 medium containing 5 μg/mL LPS. CD4+ T cells were cocultured with iPSCs-DCs, SN-iPSCs-DCs, or controls in different proportions (DCs:T cells = 1:80, 1:40, 1:20 or 1:10) in a 96-well culture plate for 72 h. The inhibition rates of CD4+ T cells by iPSCs–DCs and SN-iPSCs-DCs were analyzed with the CCK-8 assay based on the optical density (OD). Inhibition rate = (1 - OD of experimental group/OD of control group) × 100%.

***Flow cytometry***

The surface markers of iPSCs-imDCs and SN-iPSCs-DCs, the effects of iPSCs–DCs and SN-iPSCs-DCs on Treg cells *in vitro* and *in vivo*, apoptosis, and uptake of fluorescein isothiocyanate (FITC)-Dextran in cells were analyzed by flow cytometry. Cells were collected and labeled with primary anti-CD45, CD11b, CD80, CD86, MHC-II, CD11c, CD25, CD4, and FoxP3, followed by secondary Alexa-Fluor488-conjugated goat anti-rabbit IgG antibodies. The cells were analyzed using BD FACS flow cytometry, and data were analyzed using FlowJo software.

***ELISA***

After stimulation with LPS at a final concentration of 5 μg/mL for 48 h, the iPSCs-imDCs and SN-iPSCs-imDCs culture supernatants were collected. Expression of cytokines IL-2, IL-10, interferon (IFN)-γ, transforming growth factor (TGF)-β and IL-12 in the culture supernatant before and after LPS stimulation was detected by ELISA. IL-2, IL-10, IFN-γ, TGF-β and IL-12 expression in the peripheral blood of recipients at 14 d postgraft was also detected by ELISA.

***Western blotting***

The relative expression of apoptosis-related proteins caspase 3, Bcl-2, Bax, and PARP were analyzed by western blotting. After stimulating iPSCs–imDCs and SN-iPSCs-imDCs with LPS for 48 h, the total protein for the two groups was extracted with radioimmunoprecipitation assay lysis buffer and measured with a bicinchoninic acid protein assay kit. The same amount of protein from lysate samples was separated using SDS-PAGE and transferred to nitrocellulose membranes blocked with 50 g/L skimmed milk for 2 h. The membranes were incubated with primary antibodies overnight at 4 °C, followed by horseradish-peroxidase-conjugated secondary antibodies for 1 h at room temperature. The blots were visualized and detected using an ECL Western blot analysis system, and glyceraldehyde 3-phosphate dehydrogenase expression was used to normalize the data. The intensity of the western blotting bands was determined with Image J software version 1.46 (National Institutes of Health, Bethesda, MD, United States).

***Skin transplantation***

C57bl/6 mice were used as donors and Balb/c mice were used as recipients. Thirty Balb/c mice (6-7 week old, 19.9 ± 2.8 g) were randomly divided into six groups. (1) Control group: Allogeneic mouse skin graft model without treatment; (2) PBS group: 7 d before transplantation, 0.3 mL PBS was intravenously infused into the tails of the recipients; (3) iPSCs-imDCs group: 7 d before transplantation, 106 iPSCs-imDCs in 0.3 mL PBS were intravenously infused into the tails of the recipients; (4) SN-iPSCs-imDC group: 7 d before transplantation, 106 SN-iPSCs-imDCs in 0.3 mL PBS were intravenously infused into the tails of the recipients; (5) SN group: 3 d before transplantation, 30 mg/kg SN was intravenously infused into the tails of the recipients, once a day for 3 d; and (6) Cyclosporin A (CsA) group: 3 d before transplantation, 30 mg/kg CsA was intravenously infused into the tails of the recipients, once a day for 3 d. Allogeneic skin transplantation was performed according to the protocol described previously[16]. The donor mice were anesthetized with 50 mg/kg pentobarbital sodium (intraperitoneal), and back skin was harvested with blunt dissection. The donor animals were killed, and the connective tissue, fat tissue, and panniculus carnosus were removed from the skin flap to obtain 1 cm × 1 cm squares. The recipient mice were anesthetized with the same dose of pentobarbital sodium (intraperitoneal) plus 5 mg/kg carprofen (subcutaneous). Graft beds (1 cm × 1 cm) were created by dissecting the back skin, keeping the sarcolipid membranes and vessels intact. The allografted skin sections were stitched together using 4-0 silk, and 0.5 mg gentamicin was administered *per* mouse to prevent infection. The weight of the animals was recorded every 7 d for 28 d. From day 4 post-transplant, the grafts in each group were scored once a day for 24 d. Statistical evaluation of graft survival was performed using Kaplan–Meier curves and compared using log-rank tests. On day 14 post-transplant, the allografts and recipients’ spleens were removed for analysis.

***Treg cell detection in animal spleens***

The recipient spleens in both groups were ground and filtered through a 70-μm cell strainer. The CD4, CD25, and FoxP3 markers on Treg cells were analyzed by flow cytometry. Using C3H mice as an unrelated third party, the reactivity of the recipient lymphocytes in the PBS, iPSs-imDCs and SN-iPSs-imDCs groups to the donor and unrelated third party was detected.

***Hematoxylin and eosin staining***

The allografts were harvested, fixed in 4% paraformaldehyde for 24 h, dehydrated, and embedded in paraffin. Four-micrometer-thick sections were stained with hematoxylin and eosin (H&E) for morphological observation. Images were observed and photographed under the BX41 fluorescence microscope (Olympus Corporation, amplification: × 200).

***Statistical analysis***

All data were expressed as the mean ± SEM. The biotechnology experiments were repeated at least three times *in vitro*. Intergroup deviations were assessed using one-way analysis of variance, with *P* < 0.05 indicating a significant difference.

**RESULTS**

***iPSCs culture and identification***

Morphology of iPSCs was observed after culturing for 2 d, 3 d, 5 d and 6 d, and fluorescence images showing expression of Nanog+-iPSCs colonies (Figure 1A). The specific genes *Nanog*, *Rex1* and *Dppa3* and endogenous genes *Sox2*, *Klf4*, *c-Myc* and *Oct4* in the iPSCs remained stable as the number of passages increased, and no exogenous *Sox2*, *Klf4*, c-*Myc* and *Oct4* gene expression occurred (Figure 1B). Alkaline phosphatase staining of the iPSCs was positive; the cells were stained purple–black, which is an important characteristic of pluripotent stem cells (Figure 1C). Karyotype analysis showed that the iPSCs possessed a normal diploid karyotype of 40XX (Figure 1D). The differentiation potential of iPSCs into various cell types in the three germ layers was determined by analyzing teratomas generated from mouse iPSCs. After H&E staining, the intestinal epithelium (endoderm), muscle tissue (mesoderm) and nerve tissue (endoderm) were observed under a microscope (Figure 1E). The experiment demonstrated that iPSCs possessed the potential to differentiate into three germ layer tissue.

***SN enhances the differentiation of iPSCs into imDCs***

The CCK-8 assay results showed the optimal concentration of SN was 100 μM. This was the maximum concentration at which cell viability was > 95% (Figure 2A). iPSCs began to differentiate at 3 d in the first stage; bone marrow hematopoietic progenitor-like cells appeared at 6 d in the second stage; and the cells differentiated into imDC-like cells at 13 d in the third stage. After 48 h of LPS stimulation, DC-like cells appeared in large numbers, with a uniform size, short burrs, and protrusions in individual cells. Scanning electron microscopy showed that the cells were wrinkled and uniform, with burr-like protrusions on the surface. Transmission electron microscopy showed that cells contained mitochondria, ribosomes and other organelles, as well as vesicles and lysosomes of varying sizes (Figure 2B). The iPSCs that differentiated on day 6 in the second stage were collected and detected with flow cytometry. The results showed that the cell surface highly expressed the hematopoietic cell marker antigen CD45 and monocyte marker antigen CD11b (Figure 2C).

***SN-iPSCs-imDCs surface phenotypes in differentiation culture***

The cells in the iPSCs-imDCs and SN-iPSCs-imDCs groups were collected on days 5, 10 and 13 in the third stage after 48 h of LPS stimulation and visualized by flow cytometry. On days 5, 10 and 13, expression of CD80, CD86, and MHC-II on the cell surface of the two groups was lower, and expression of CD11c was higher. After LPS stimulation of iPSCs-imDCs and SN-iPSCs-imDCs for 48 h, expression of CD80, CD86 and MHC-II increased, while expression of CD11c decreased. The positive proportion of CD80, CD86 and MHC-II on the surface of the SN-iPSC-DCs group was significantly lower than that in the iPSC-DCs group, while expression of CD11c was significantly higher (Figure 3).

***SN-iPSCs–imDCs suppressed T-cell proliferation and enhanced Treg cell proliferation***

The spleen cells of BALB/c mice were isolated. The purity of T cells detected by CD3 (FITC)-specific fluorescent antibody after magnetic bead separation was 93.42 ± 2.64% (Figure 4A). iPSCs-imDCs, SN-iPSCs-imDCs and LPS were cocultured with sorted T-cells for 72 h, respectively. The ratio of DCs:T cells was 1:10, 1:20, 1:40 and 1:80 in each group. The proliferation of stimulated T cells in the SN-iPSCs-DCs group was significantly lower than that in the LPS group (Figure 4B). When the ratio of imDCs:T cells was 1:40, the proliferation of stimulated T cells in the SN-iPSCs-DCs group was significantly lower than that in the iPSCs-DCs group (Figure 4C). iPSCs-DCs and SN-iPSCs-DCs were cocultured with CD4+ T cells at a ratio of 1:40 for 72 h, and the inhibition of CD4+ T cells in each group was determined with the CCK-8 assay. The results showed that the ability of SN-iPSCs-DCs to inhibit proliferation of CD4+ T cells was better than that of iPSCs–DCs (Figure 4D). Flow cytometry showed that iPSCs-DCs and SN-iPSCs-DCs had the ability to induce CD4+CD25+FoxP3+ Treg cell proliferation. The ability of SN-iPSCs-DCs to induce proliferation of CD4+CD25+FoxP3+ T cells was significantly higher than that of iPSCs-DCs (Figure 4E). The cell culture supernatants were collected, and ELISA was used to detect cytokines IL-2, IL-12, IFN-γ, IL-10 and TGF-β. The levels of IL-2, IL-12 and IFN-γ in the culture medium of the SN-iPSCs-DCs group were significantly lower than those of the iPSCs-DCs group, whereas the levels of IL-10 and TGF-β were significantly higher in the SN-iPSCs-DCs group (Figure 4F).

***Endocytotic capacity in SN-iPSCs-imDCs and SN-iPSCs-DCs***

iPSCs-imDCs and SN-iPSCs-imDCs were treated with LPS (5 μg/mL) for 48 h to obtain iPSCs-DCs and SN-iPSCs-DCs. The antigen uptake assays used FITC-Dextran to examine the endocytic ability in the generated SN-iPSCs-imDCs and SN-iPSCs-DCs. Antigen uptake was greater at 37 °C than 4 °C in the same group at the same time. Antigen uptake in SN-iPSCs-imDCs was greater than that observed in the iPSCs-imDCs at 37 °C. Endocytotic capacity of FITC-Dextran was also significantly higher in SN-iPSCs-DCs than iPSCs-DCs (Figure 5).

***Apoptosis of SN-iPSCs-DCs stimulated with LPS***

iPSCs-imDCs and SN-iPSCs-imDCs were treated with LPS (5 μg/mL) for 48 h, and apoptosis was analyzed by flow cytometry. The apoptosis rate of SN-iPSCs-DCs was significantly higher than that of iPSCs-DCs (Figure 6A). Expression of apoptosis-related proteins caspase 3, Bax, Bcl-2 and PARP was analyzed by western blotting. Protein expression levels of cleaved caspase 3, Bax and cleaved PARP in SN-iPSCs-DCs was higher than in iPSCs-DCs, and the level of *Bcl-2* gene was lower (Figure 6B).

***SN-iPSCs-imDCs immunization prolonged survival of allogeneic skin grafts***

The weight of mice in the Sham group increased gradually, whereas the weight in other groups decreased from day 7 postgraft, especially in the CsA group. Compared with the iPSCs-imDCs group, the weight of mice in the SN-iPSCs-imDCs group increased significantly (Figure 7A). Histology showed lymphocyte infiltration around the grafted skin in the PBS group on day 7 postgraft. In contrast, lymphocyte infiltration was markedly reduced in the iPSCs-imDCs and SN-iPSCs-imDCs groups, especially in the latter group (Figure 7B). The graft rejection score was reduced in the SN-iPSCs-imDCs group than in the iPSCs-imDCs group (Figure 7C). We also found that donor SN-iPSCs-imDCs prolonged allograft survival [PBS control: *n* = 5, median survival time (MST) 8.2 d; iPSCs-imDCs: *n* = 5, MST 17 d; SN-iPSCs-imDCs: MST 22 d; SN: *n* = 5, MST 15.8 d; CsA: *n* = 5, MST 26.2 d] (Figure 7D).

***SN-iPSCs–imDCs immunization suppressed T cells and increased activated Treg cells in allografts***

We found that the ratios of CD4+CD25+ Treg cells/CD4+ T cells in spleen and CD4+CD25+FoxP3+ Treg cells/CD4+CD25+ Treg cells were significantly increased in the iPSCs-imDCs and SN-iPSCs-imDCs groups than in the SN group. Compared with iPSCs-imDCs, the SN-iPSCs-imDCs group was higher (Figure 8A and B). The reactivity of spleen lymphocytes to donor mouse lymphocytes in the iPSCs-imDCs and SN-iPSCs-imDCs groups was significantly lower than that in unrelated third-party C3H mice. The SN-iPSCs-imDCs group had significantly less reactivity to donor lymphocytes than the iPSCs-imDCs group had (Figure 8C), which confirmed that the infusion of donor-derived SN-iPSCs-imDCs could induce donor-specific immune hyporesponsiveness and that SN-iPSCs-imDCs were significantly better than iPSCs-imDCs at this task. Proinflammatory cytokines such as IL-2, IL-12 and IFN-γ were downregulated, and anti-inflammatory cytokines such as IL-10 and TGF-β were upregulated in the serum from SN-iPSCs-imDC-treated recipients compared with the levels in iPSCs-imDCs-treated recipients (Figure 8D).

**DISCUSSION**

imDCs play an important role in immune tolerance but are difficult to obtain in large quantities. At present, DCs can be obtained from bone marrow mesenchymal stem cells, but the process is difficult due to the significant trauma involved. DCs can also be obtained from cord blood and embryonic stem cells; however, ethical issues prevent the clinical application of these cells. iPSCs have been adopted in the biological and medical fields because they can be obtained from a wide range of sources and are free of ethical issues[17]. Previous research and our study confirmed that iPSCs cocultured with OP9 feeder cells could differentiate into imDCs under the influence of GM-CSF and IL-4[9,18].

The immune function of DCs *in vivo* is closely related to their maturity. Mature DCs provide activation signals to initiate immune responses unlike imDCs, which cannot provide a signal for T-cell activation or induce T-cell clonal energy due to the lack of expression of costimulatory molecules on their surface[19,20]. imDCs induce T cells to differentiate into Th2 cells, inhibit secretion of inflammatory factors (IL-2, IFN-γ, *etc.*), and increase secretion of anti-inflammatory factors (IL-10, TSLP, TGF-β, *etc.*), eventually inducing an increase in the proportion of Treg cells[21-23]. The increased Treg cells subsequently downregulate expression of costimulatory molecules CD40, CD80 and CD86 in the NF-κB pathway; upregulate inhibitory receptors; induce production of tolerogenic DCs, including imDCs; and maintain the immature state of imDCs[24], thus forming a positive feedback loop that ultimately induces immunotolerance[25]. Due to the strong phagocytic function of imDCs, they mature quickly and lose the ability to induce immunotolerance under antigen stimulation *in vivo*. At present, the methods for inhibiting the maturation of imDCs mainly include: (1) Blocking the surface costimulatory molecules of imDCs by genetic modification[26-28]; (2) Blocking expression of specific molecules on the surface of imDCs with drugs[29]; (3) Using immunomodulatory factors to inhibit maturation of imDCs[30,31]; and (4) Using immunosuppressive agents to keep imDCs immature[32]. However, there are some inevitable flaws with these strategies. Firstly, the efficacy of gene modification is low, and there are potential biosafety and immunogenicity issues. Secondly, controlling the concentration of imDCs in the body through drug intervention is difficult due to large individual differences. Thirdly, when cytokines are infused into the body, allograft antigen stimulation, microbial infection, and other factors make it difficult for imDCs to maintain their immature state for a long time. Therefore, a strategy to stably maintain the immature state of imDCs has become a primary challenge at present.

In recent years, the potential of SN application in transplantation immunity has received increasing attention. It has been reported that SN can stimulate the differentiation of peripheral blood mononuclear cells into imDCs and further inhibit the maturation of imDCs[13]. SN can reduce the expression of CCR5 and CCR7 on DCs, inhibit secretion of chemokines CXCL9 and CXCL10, block expression of TLR2 and TLR4 in peripheral blood DCs, stimulate differentiation of monocytes into imDCs, and inhibit their further maturation[33]. Due to the mild drug properties of SN, short half-life, lack of toxicity below a certain dose, and lack of mutagenicity, the compound was used to induce bone marrow stem cells to differentiate into imDCs (SN-BM-imDCs). The results demonstrated that the infusion of donor SN-BM-imDCs could significantly prolong the graft survival span in recipient rats and induce the proliferation of Treg cells *in vivo*[13]. In this study, we successfully obtained SN-iPSCs-imDCs and confirmed these cells had the morphological structure and biological function of imDCs and retained a stable immature phenotype, even in the presence of LPS. Treg cells generated by SN-iPSCs-imDCs immunization were donor-specific and played a key role in tolerance induction and maintenance. However, the study did not explore the efficiency of directed differentiation in detail. In the future, we will apply SN at different stages of iPSCs differentiation and investigate the highest differentiation efficiency of SN-iPSCs-imDCs.

The apoptosis of DCs is closely related to immune status. It has been reported that some pathogens, tumors, and drugs promote the apoptosis of DCs, which can lead to a reduction in antigens presented to T cells. The results indicate that imDCs phagocytose apoptotic DCs, transform into tolerance DCs, and then induce naïve T cells to differentiate into FoxP3+ Treg cells[34]. Some studies have also confirmed that SN could inhibit glioblastoma by inducing mitochondria-dependent apoptosis and autophagy by PI3K/AKT/mTOR and AMPK/mTOR pathway[33,34]. However, there is no report on SN-induced apoptosis of DCs. In this study, we found that apoptosis-related protein expression levels in SN-iPSCs-imDCs were significantly higher than those in iPSCs-imDCs. This may be one of the mechanisms by which SN-iPSCs-imDCs induce immune hyporesponsiveness or tolerance.

Donor immune cell infusion therapy can enhance recipient immune negative regulation, which is the most effective method to resolve graft rejection[35,36]. In this study, we established a skin transplantation model of C57bl/6 as the donor and BALB/c mice as the recipient as an alternative to the common organ transplantation model. Balb/c mice recipients were immunized with SN-iPSCs-imDCs or iPSCs-imDCs 7 d before skin grafts, and Treg cells were significantly increased in Balb/c mice splenocytes after transplantation. The survival span of C57bl/6 skin grafts was significantly prolonged in immunized Balb/c recipients with a donor-specific pattern, which was consistent with the reports of DCs coordinating the development and homeostasis of organ-specific Treg cells[37,38]. The reason for the induction of tolerance may be that the donor-type SN-iPSCs-imDCs act as a primary vaccine, while the alloantigen acts as a secondary vaccine[16], thereby promoting the expansion and continuous activation of donor-specific Treg cells.

However, there were some limitations to our study. Firstly, the procedure for inducing the differentiation of iPSCs into DCs comprised three stages. Further research is required to establish at which stage intervention with SN improves induction. Secondly, cell density is an important factor determining cell fate. We aim to try different cell densities on different effects of immunotolerance in organ transplantation to obtain the optimal protocol in our future studies. Lastly, we combined SN and mouse iPSCs technology to obtain SN-iPSCs-imDCs. In the future, we will combine SN and human iPSCs technology to induce immunotolerance in a clinical setting.

**CONCLUSION**

We combined SN and iPSCs technology for the first time and successfully obtained SN-iPSCs-imDCs. These cells could be acquired in large quantities, remained in an immature state for a long time, and induced immunotolerance by inhibiting CD4+ T cells and increasing CD4+CD25+FoxP3+ Treg cells. The results provide a theoretical basis for the use of SN-iPSCs-imDCs in the field of transplantation immunotolerance.

**ARTICLE HIGHLIGHTS**

***Research background***

Immature dendritic cells (imDCs) play a vital role in the induction of donor-specific transplant immune tolerance. However, these cells have limitations, such as rapid maturation and a short lifespan *in vivo*. The induced pluripotent stem cells (iPSCs) could differentiate to imDCs and sinomenine (SN) could inhibit the maturation of imDCs. Therefore, the iPSCs-derived imDCs treated with SN are expected to become promising seeding cells for inducing immune tolerance in organ transplantation.

***Research motivation***

The immune chronic rejection after solid organ transplantation is serious and still lacks an effective treatment.

***Research objectives***

The objective of our study was to evaluate the therapeutic effects of SN-iPSCs-imDC induced immune tolerance *in* *vitro* andallogeneic skin graft Mouse model.

***Research methods***

Mouse iPSCs were induced to differentiate into imDCs in a culture medium with or without SN (iPSCs-imDCs and SN-iPSCs-imDCs). The related surface markers, the effects on T-cell stimulatory function, regulatory T (Treg) cell proliferative function, cytokine expression levels, cell endocytic capacity and cell apoptosis of iPSCs-imDCs and SN-iPSCs-imDCs in vitro and *in vivo* were analyzed. The induced immunology tolerance of SN-iPSCs-DCs was evaluated by treated the recipients Balb/c skin graft mice. Statistical evaluation of graft survival was performed using Kaplan-Meier curves.

***Research results***

We successfully obtained iPSCs-imDCs and SN-iPSCs-imDCs. SN-iPSCs-imDCs exhibited higher CD11c levels, lower CD80, CD86 and MHC-II levels, worse T-cell stimulatory function, and higher Treg-cells proliferative function compared with iPSCs-imDCs. Additionally, the levels of interleukin (IL)-2, IL-12, interferon-γ in SN-iPSCs-imDCs were lower than those in iPSCs-imDCs, whereas IL-10 and transforming growth factor-β levels were higher. Moreover, the cell endocytic capacity and apoptosis rate in SN-iPSCs-imDCs was significantly higher. In Balb/c mice recipients immunized with iPSCs-imDCs or SN-iPSCs-imDCs 7 d before skin grafts, Tregs were significantly increased in the spleen after transplantation and the survival span of C57bl/6 skin grafts was significantly prolonged in immunized Balb/c recipients with a donor-specific pattern in SN-iPSCs-imDCs treated group.

***Research conclusions***

The SN-iPSCs-imDCs have potential applications for the induction of immune tolerance following organ transplantation.

***Research perspectives***

TheSN-iPSCs-imDCs could induce immune immune hyporesponsiveness, even immune tolerance, which may be an effective strategy to treat immune chronic rejection after organ tranplantation.

**REFERENCES**

1 **Hariharan S**, Israni AK, Danovitch G. Long-Term Survival after Kidney Transplantation. *N Engl J Med* 2021; **385**: 729-743 [PMID: 34407344 DOI: 10.1056/NEJMra2014530]

2 **Lai X**, Zheng X, Mathew JM, Gallon L, Leventhal JR, Zhang ZJ. Tackling Chronic Kidney Transplant Rejection: Challenges and Promises. *Front Immunol* 2021; **12**: 661643 [PMID: 34093552 DOI: 10.3389/fimmu.2021.661643]

3 **Mackern-Oberti JP**, Llanos C, Vega F, Salazar-Onfray F, Riedel CA, Bueno SM, Kalergis AM. Role of dendritic cells in the initiation, progress and modulation of systemic autoimmune diseases. *Autoimmun Rev* 2015; **14**: 127-139 [PMID: 25449681 DOI: 10.1016/j.autrev.2014.10.010]

4 **Suuring M**, Moreau A. Regulatory Macrophages and Tolerogenic Dendritic Cells in Myeloid Regulatory Cell-Based Therapies. *Int J Mol Sci* 2021; **22** [PMID: 34360736 DOI: 10.3390/ijms22157970]

5 **Machcińska M**, Kotur M, Jankowska A, Maruszewska-Cheruiyot M, Łaski A, Kotkowska Z, Bocian K, Korczak-Kowalska G. Cyclosporine A, in Contrast to Rapamycin, Affects the Ability of Dendritic Cells to Induce Immune Tolerance Mechanisms. *Arch Immunol Ther Exp (Warsz)* 2021; **69**: 27 [PMID: 34632525 DOI: 10.1007/s00005-021-00632-7]

6 **Zhang X**, Chang A, Zou Y, Xu H, Cui J, Chen Z, Li Y, Du Y, Wu J, Yu J, Du X. Aspirin Attenuates Cardiac Allograft Rejection by Inhibiting the Maturation of Dendritic Cells *via* the NF-κB Signaling Pathway. *Front Pharmacol* 2021; **12**: 706748 [PMID: 34483913 DOI: 10.3389/fphar.2021.706748]

7 **Collin M**, Ginhoux F. Human dendritic cells. *Semin Cell Dev Biol* 2019; **86**: 1-2 [PMID: 29727728 DOI: 10.1016/j.semcdb.2018.04.015]

8 **Guo R**, Li W, Li Y, Li Y, Jiang Z, Song Y. Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells. *Exp Hematol Oncol* 2022; **11**: 27 [PMID: 35568954 DOI: 10.1186/s40164-022-00285-y]

9 **Senju S**, Haruta M, Matsunaga Y, Fukushima S, Ikeda T, Takahashi K, Okita K, Yamanaka S, Nishimura Y. Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cells. *Stem Cells* 2009; **27**: 1021-1031 [PMID: 19415766 DOI: 10.1002/stem.33]

10 **Xiong L**, Yang L. Effects of alkaloid sinomenine on levels of IFN-γ, IL-1β, TNF-α and IL-6 in a rat renal allograft model. *Immunotherapy* 2012; **4**: 785-791 [PMID: 22947007 DOI: 10.2217/imt.12.80]

11 **Xu YY**, Wang DM, Liang HS, Liu ZH, Li JX, Wang MJ, Chen XM, Balak DMW, Radstake TRDJ, Huang RY, Lu CJ. The Role of Th17/Treg Axis in the Traditional Chinese Medicine Intervention on Immune-Mediated Inflammatory Diseases: A Systematic Review. *Am J Chin Med* 2020; **48**: 535-558 [PMID: 32345031 DOI: 10.1142/S0192415X20500275]

12 **Li L**, Luo Z, Song Z, Zheng L, Chen T. Pre-transplant infusion of donor-derived dendritic cells maintained at the immature stage by sinomenine increases splenic Foxp3+ Tregs in recipient rats after renal allotransplantation. *Transpl Immunol* 2017; **45**: 22-28 [PMID: 28802587 DOI: 10.1016/j.trim.2017.08.004]

13 **Wang Y**, Ma D, Jie Y, Wu Y, Pan Z. Sinomenine can prolong high-risk corneal graft survival in a rat model. *Immunotherapy* 2012; **4**: 581-586 [PMID: 22788126 DOI: 10.2217/imt.12.45]

14 **Chen Y**, Yang C, Jin N, Xie Z, Fei L, Jia Z, Wu Y. Sinomenine promotes differentiation but impedes maturation and co-stimulatory molecule expression of human monocyte-derived dendritic cells. *Int Immunopharmacol* 2007; **7**: 1102-1110 [PMID: 17570327 DOI: 10.1016/j.intimp.2007.04.007]

15 **Wang DD**, Wu XY, Dong JY, Cheng XP, Gu SF, Olatunji OJ, Li Y, Zuo J. Qing-Luo-Yin Alleviated Experimental Arthritis in Rats by Disrupting Immune Feedback Between Inflammatory T Cells and Monocytes: Key Evidences from Its Effects on Immune Cell Phenotypes. *J Inflamm Res* 2021; **14**: 7467-7486 [PMID: 35002280 DOI: 10.2147/JIR.S346365]

16 **Cheng CH**, Lee CF, Fryer M, Furtmüller GJ, Oh B, Powell JD, Brandacher G. Murine Full-thickness Skin Transplantation. *J Vis Exp* 2017 [PMID: 28117792 DOI: 10.3791/55105]

17 **Radojević D**, Tomić S, Mihajlović D, Tolinački M, Pavlović B, Vučević D, Bojić S, Golić N, Čolić M, Đokić J. Fecal microbiota composition associates with the capacity of human peripheral blood monocytes to differentiate into immunogenic dendritic cells *in vitro*. *Gut Microbes* 2021; **13**: 1-20 [PMID: 33970783 DOI: 10.1080/19490976.2021.1921927]

18 **Cai S**, Hou J, Fujino M, Zhang Q, Ichimaru N, Takahara S, Araki R, Lu L, Chen JM, Zhuang J, Zhu P, Li XK. iPSC-Derived Regulatory Dendritic Cells Inhibit Allograft Rejection by Generating Alloantigen-Specific Regulatory T Cells. *Stem Cell Reports* 2017; **8**: 1174-1189 [PMID: 28434942 DOI: 10.1016/j.stemcr.2017.03.020]

19 **Zhao L**, Liu P, Xie W, Zhang S, Thieme S, Zitvogel L, Kroemer G, Kepp O. A genotype-phenotype screening system using conditionally immortalized immature dendritic cells. *STAR Protoc* 2021; **2**: 100732 [PMID: 34430908 DOI: 10.1016/j.xpro.2021.100732]

20 **Pang XL**, Wang ZG, Liu L, Feng YH, Wang JX, Xie HC, Yang XL, Li JF, Feng GW. Immature dendritic cells derived exosomes promotes immune tolerance by regulating T cell differentiation in renal transplantation. *Aging (Albany NY)* 2019; **11**: 8911-8924 [PMID: 31655796 DOI: 10.18632/aging.102346]

21 **Nomura M**, Hodgkinson SJ, Tran GT, Verma ND, Robinson C, Plain KM, Boyd R, Hall BM. Cytokines affecting CD4+T regulatory cells in transplant tolerance. II. Interferon gamma (IFN-γ) promotes survival of alloantigen-specific CD4+T regulatory cells. *Transpl Immunol* 2017; **42**: 24-33 [PMID: 28487237 DOI: 10.1016/j.trim.2017.05.002]

22 **Jia L**, Lu J, Zhou Y, Tao Y, Xu H, Zheng W, Zhao J, Liang G, Xu L. Tolerogenic dendritic cells induced the enrichment of CD4+Foxp3+ regulatory T cells *via* TGF-β in mesenteric lymph nodes of murine LPS-induced tolerance model. *Clin Immunol* 2018; **197**: 118-129 [PMID: 30248398 DOI: 10.1016/j.clim.2018.09.010]

23 **Akkaya B**, Oya Y, Akkaya M, Al Souz J, Holstein AH, Kamenyeva O, Kabat J, Matsumura R, Dorward DW, Glass DD, Shevach EM. Regulatory T cells mediate specific suppression by depleting peptide-MHC class II from dendritic cells. *Nat Immunol* 2019; **20**: 218-231 [PMID: 30643268 DOI: 10.1038/s41590-018-0280-2]

24 **Xiao J**, Zhang J, Li X, Dai X, Wang J, He Y, Wei L, Shi J, Gong N. Downregulation of Blimp1 inhibits the maturation of bone marrow-derived dendritic cells. *Int J Mol Med* 2019; **43**: 1094-1104 [PMID: 30483767 DOI: 10.3892/ijmm.2018.4000]

25 **Ghimire S**, Matos C, Caioni M, Weber D, Peter K, Holler E, Kreutz M, Renner K. Indoxyl 3-sulfate inhibits maturation and activation of human monocyte-derived dendritic cells. *Immunobiology* 2018; **223**: 239-245 [PMID: 29100619 DOI: 10.1016/j.imbio.2017.10.014]

26 **Liu WH**, Liu JJ, Wu J, Zhang LL, Liu F, Yin L, Zhang MM, Yu B; PLOS ONE Editors. Retraction: Novel Mechanism of Inhibition of Dendritic Cells Maturation by Mesenchymal Stem Cells *via* Interleukin-10 and the JAK1/STAT3 Signaling Pathway. *PLoS One* 2018; **13**: e0194455 [PMID: 29538460 DOI: 10.1371/journal.pone.0194455]

27 **Dong Z**, Chen Y, Peng Y, Wang F, Yang Z, Huang G, Chen Y, Yuan Z, Cao T, Peng Y. Concurrent CCR7 Overexpression and RelB Knockdown in Immature Dendritic Cells Induces Immune Tolerance and Improves Skin-Graft Survival in a Murine Model. *Cell Physiol Biochem* 2017; **42**: 455-468 [PMID: 28578354 DOI: 10.1159/000477593]

28 **Wang YC**, Chen RF, Brandacher G, Lee WPA, Kuo YR. The suppression effect of dendritic cells maturation by adipose-derived stem cells through TGF-β1 related pathway. *Exp Cell Res* 2018; **370**: 708-717 [PMID: 30053444 DOI: 10.1016/j.yexcr.2018.07.037]

29 **Wang J**, Wang J, Hong W, Zhang L, Song L, Shi Q, Shao Y, Hao G, Fang C, Qiu Y, Yang L, Yang Z, Wang J, Cao J, Yang B, He Q, Weng Q. Optineurin modulates the maturation of dendritic cells to regulate autoimmunity through JAK2-STAT3 signaling. *Nat Commun* 2021; **12**: 6198 [PMID: 34707127 DOI: 10.1038/s41467-021-26477-4]

30 **Švajger U**, Rožman PJ. Recent discoveries in dendritic cell tolerance-inducing pharmacological molecules. *Int Immunopharmacol* 2020; **81**: 106275 [PMID: 32044665 DOI: 10.1016/j.intimp.2020.106275]

31 **Wang Q**, Cun D, Xu D, Lin L, Jiao J, Zhang L, Xi C, Li W, Chen P, Hu M. Myd88 knockdown with RNA interference induces *in vitro* immune hyporesponsiveness in dendritic cells from rhesus monkeys. *Immunogenetics* 2022; **74**: 303-312 [PMID: 35303127 DOI: 10.1007/s00251-022-01260-x]

32 **Ter Braake D**, Benne N, Lau CYJ, Mastrobattista E, Broere F. Retinoic Acid-Containing Liposomes for the Induction of Antigen-Specific Regulatory T Cells as a Treatment for Autoimmune Diseases. *Pharmaceutics* 2021; **13** [PMID: 34834364 DOI: 10.3390/pharmaceutics13111949]

33 **Zheng X**, Li W, Xu H, Liu J, Ren L, Yang Y, Li S, Wang J, Ji T, Du G. Sinomenine ester derivative inhibits glioblastoma by inducing mitochondria-dependent apoptosis and autophagy by PI3K/AKT/mTOR and AMPK/mTOR pathway. *Acta Pharm Sin B* 2021; **11**: 3465-3480 [PMID: 34900530 DOI: 10.1016/j.apsb.2021.05.027]

34 **Castenmiller C**, Keumatio-Doungtsop BC, van Ree R, de Jong EC, van Kooyk Y. Tolerogenic Immunotherapy: Targeting DC Surface Receptors to Induce Antigen-Specific Tolerance. *Front Immunol* 2021; **12**: 643240 [PMID: 33679806 DOI: 10.3389/fimmu.2021.643240]

35 **Brody DL**. Transplantation Therapy with Clinically Relevant Sources of Cells in Experimental Traumatic Brain Injury. *J Neurotrauma* 2021; **38**: 2633 [PMID: 34596456 DOI: 10.1089/neu.2021.29117.editorial]

36 **García Ruiz de Gordejuela A**, Ibarzabal A, Osorio J. Bariatric Surgery and Solid-Organ Transplantation. *Transplant Proc* 2022; **54**: 87-90 [PMID: 34973842 DOI: 10.1016/j.transproceed.2021.11.008]

37 **Leventhal DS**, Gilmore DC, Berger JM, Nishi S, Lee V, Malchow S, Kline DE, Kline J, Vander Griend DJ, Huang H, Socci ND, Savage PA. Dendritic Cells Coordinate the Development and Homeostasis of Organ-Specific Regulatory T Cells. *Immunity* 2016; **44**: 847-859 [PMID: 27037189 DOI: 10.1016/j.immuni.2016.01.025]

38 **Zhuang Q**, Cai H, Cao Q, Li Z, Liu S, Ming Y. Tolerogenic Dendritic Cells: The Pearl of Immunotherapy in Organ Transplantation. *Front Immunol* 2020; **11**: 552988 [PMID: 33123131 DOI: 10.3389/fimmu.2020.552988]

**Footnotes**

**Institutional animal care and use committee statement:** All of the procedures and ethics of animal use were reviewed and approved by the Biomedical Ethics Committee of Shaanxi Provicial People’s Hospital, No. 2021-198.

**Conflict-of-interest statement:** All theauthors report no relevant conflicts of interest for this article.

**Data sharing statement:** No additional data are available.

**ARRIVE guidelines statement:** The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** February 25, 2022

**First decision:** April 19, 2022

**Article in press:** July 11, 2022

**Specialty type:** Cell and tissue engineering

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Tang BP, China; Wahid M, Pakistan **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Fan JR


**Figure Legends**




**Figure 1 Induced pluripotent stem cells culture and identification.** A: Morphological observation and cell cloning of induced pluripotent stem cells (iPSCs) at 2 d, 3 d, 5 d and 6 d and Nanog+-iPSCs in culture; B: Quantitative polymerase chain reaction identification; C: Alkaline phosphatase staining; D: Chromosome identification; E: Teratoma formation; red arrow = intestinal epithelium (endoderm), green arrow = muscle tissue (mesoderm), and black arrow = nerve tissue (endoderm). AKP: Alkaline phosphatase.




**Figure 2 Morphological changes from induced pluripotent stem cells to induced pluripotent stem cells-dendritic cells.** A: The optimal concentration of sinomenine (SN) was 100 μM; B: Morphological changes from induced pluripotent stem cells (iPSCs) to iPSCs-dendritic cells (DCs) at 3 d in the first stage; iPSC-derived hematopoietic cells at 6 d in the second stage; and iPSC-derived imDCs at 13 d in the third stage under the influence of SN. After 48 h of lipopolysaccharide stimulation, the morphology of SN-iPSCs-DCs in phase contrast microscopy, scanning electron microscopy and transmission electron microscopy; C: Expression of the cell surface markers CD45 and CD11b from iPSCs to iPSCs–DCs under the influence of SN on day 6 in the second stage. SN: Sinomenine.




**Figure 3 Immature dendritic cells surface phenotypes in differentiation culture.** CD80, CD86, MHC-II and CD11c expression from induced pluripotent stem cells (iPSCs) to iPSCs-immature dendritic cells in the presence of sinomenine on days 5, 10 and 13 in stage 3 and after lipopolysaccharide stimulation for 48 h. Compared with iPSCs-dendritic cells group at the same time, a*P* < 0.05. SN: Sinomenine; iPSCs: Induced pluripotent stem cells; imDCs: Immature dendritic cells.




**Figure 4 Sinomenine-induced pluripotent stem cells–immature dendritic cells suppress T cell proliferation and enhanced regulatory T cell proliferation.** A: Purity of CD3+ T cells after sorting; B: Mixed lymphocyte reaction at different proportions of immature dendritic cells: CD3+ T cells. Compared with induced pluripotent stem cells-dendritic cells (iPSCs-DCs) group, a*P* < 0.05; C: Purity of CD4+ T cells after sorting; D: Mixed culture of iPSCs-DCs or sinomenine (SN)-iPSCs-DCs and CD4+ T cells at 1:40. Compared with iPSCs-DCs group, a*P* < 0.05; E: Effects of iPSCs-DCs or SN-iPSCs-DCs on regulatory T (Treg) cell proliferation. Compared with iPSCs-DCs group, a*P* < 0.05; F: Cytokine levels in supernatants from cocultured DCs and Treg cells. Compared with iPSCs-DCs group, a*P* < 0.05. SN: Sinomenine; iPSCs: Induced pluripotent stem cells; DCs: Dendritic cells; IL: Interleukin; IFN: Interferon; TGF-β: Transforming growth factor-β.




**Figure 5 Endocytotic capacity in sinomenine-induced pluripotent stem cells-immature dendritic cells and sinomenine-induced pluripotent stem cells-dendritic cells.** Antigen uptake in induced pluripotent stem cells (iPSCs)-immature dendritic cells (imDCs) and sinomenine (SN)-iPSCs-imDCs. Compared with iPSCs-imDCs group, a*P* < 0.05; Antigen uptake in iPSCs-DCs and SN-iPSCs-DCs. Compared with iPSCs-DCs group, a*P* < 0.05. SN: Sinomenine; iPSCs: Induced pluripotent stem cells; DCs: Dendritic cells; imDCs: Immature dendritic cells.



**Figure 6 Apoptosis of induced pluripotent stem cells-dendritic cells and sinomenine-induced pluripotent stem cells-dendritic cells stimulated with lipopolysaccharide.** A: Apoptosis rate in induced pluripotent stem cells-dendritic cells (iPSCs-DCs) and sinomenine (SN)-iPSCs-DCs stimulated with lipopolysaccharide (LPS). Compared with iPSCs-DCs group, a*P* < 0.05; B: Apoptosis-related protein expression in iPSCs-DCs and SN-iPSCs-DCs stimulated with LPS. Compared with iPSCs-DCs group, a*P* < 0.05. SN: Sinomenine; iPSCs: Induced pluripotent stem cells; DCs: Dendritic cells; PARP: Poly(ADP-ribose) polymerase; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase.



**Figure 7 Sinomenine-induced pluripotent stem cells–immature dendritic cells immunization prolonged survival of allogeneic skin grafts.** A: Body weight in all groups. Compared with PBS in the same time, a*P* < 0.05. Compared with induced pluripotent stem cells-immature dendritic cells group in the same time, b*P* < 0.05; B: Hematoxylin and eosin staining in all groups; C: Graft scores in all groups; D: Survival curves for all groups. SN: Sinomenine; iPSCs: Induced pluripotent stem cells; DCs: Dendritic cells; imDCs: Immature dendritic cells.



**Figure 8 Sinomenine-induced pluripotent stem cells-immature dendritic cells immunization suppressed T cells and increased activated regulatory T cells in allografts.** A: Sinomenine (SN)-induced pluripotent stem cells (iPSCs)-immature dendritic cells (imDCs) increased the ratio of CD4+CD25+ regulatory T (Treg) cells/CD4+ T cells in spleen. Compared with PBS group, a*P* < 0.05. Compared with iPSCs-imDCs group, b*P* < 0.05. Compared with SN group, c*P* < 0.05; B: SN-iPSCs-imDCs increased the ratio of CD4+CD25+FoxP3+ Treg cells/CD4+CD25+ Treg cells in spleen. Compared with iPSCs-imDCs group, b*P* < 0.05. Compared with SN group, c*P* < 0.05; C: Reactivity of recipient lymphocytes to donor or unrelated third-party lymphocytes. Compared to third-party lymphocytes, a*P* < 0.05. Compared with iPSCs-imDCs group, b*P* < 0.05; D: SN-iPSCs-imDCs downregulated proinflammatory cytokines and upregulated anti-inflammatory cytokines. Compared with PBS group, a*P* < 0.05. Compared with iPSCs-imDCs group, b*P* < 0.05. SN: Sinomenine; iPSCs: Induced pluripotent stem cells; DCs: Dendritic cells; imDCs: Immature dendritic cells; IL: Interleukin; IFN: Interferon; TGF-β: Transforming growth factor-β.

**Table 1 Primer sequences of polymerase chain reaction**

|  |  |
| --- | --- |
| **Gene** | **Primer sequences** |
| *Dppa3* | F: 5′-TGTGGAGAACAAGAGTGA-3′ |
| R: 5′-CTCAATCCGAACAAGTCTT-3′ |
| *Nanog* | F: 5′-CTCAAGTCCTGAGGCTGACA-3′ |
| R: 5′-TGAAACCTGTCCTTGAGTGC-3′ |
| *Rex1* | F: 5′-CAGCCAGACCACCATCTGTC-3′ |
| R: 5′-GTCTCCGATTTGCATATCTCCTG-3′ |
| *endo-Sox2* | F: 5′-AGGGCTGGGAGAAAGAAGAG-3′ |
| R: 5′-CCGCGATTGTTGTGATTAGT-3′ |
| *endo-Klf4* | F: 5′-AACATGCCCGGACTTACAAA-3′ |
| R: 5′-TTCAAGGGAATCCTGGTCTTC-3′ |
| *endo-Oct4* | F: 5′-TAGGTGAGCCGTCTTTCCAC-3′ |
| R: 5′-GCTTAGCCAGGTTCGAGGAT-3′ |
| *endo-c-Myc* | F: 5′-TAACTCGAGGAGGAGCTGGA-3′ |
| R: 5′-GCCAAGGTTGTGAGGTTAGG-3′ |
| *exo-Sox2* | F: 5′-GGGTGGACCATCCTCTAGAC-3′ |
| R: 5′-GGGCTGTTCTTCTGGTTG-3′ |
| *exo-Klf4* | F: 5′-GGGTGGACCATCCTCTAGAC-3′ |
| R: 5′-GCTGGACGCAGTGTCTTCTC-3′ |
| *exo-Oct4* | F: 5′-GGGTGGACCATCCTCTAGAC-3′ |
| R: 5′-CCAGGTTCGAGAATCCAC-3′ |
| *exo-c-Myc* | F: 5′-GGGTGGACCATCCTCTAGAC-3′ |
| R: 5′-CCTCGTCGCAGATGAAATAG-3′ |
| *β-actin* | F: 5′GTGGGCCGCTCTAGGCACCAA-3′ |
| R: 5′CTCTTTGATGTCACGCACGATTTC-3′ |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**